Agios Pharmaceuticals (AGIO) Enterprise Value (2012 - 2026)

Agios Pharmaceuticals has reported Enterprise Value for 15 years, with the latest figure at -$737.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 17.5% year-over-year to -$737.0 million; the trailing twelve-month figure through Mar 2026 stood at -$737.0 million (up 17.5% YoY), and the FY2025 full-year result was -$854.4 million, up 4.4% from the prior year.
• Enterprise Value for Q1 2026 stood at -$737.0 million, up from -$854.4 million in the prior quarter.
• The five-year high for Enterprise Value was -$569.9 million in Q2 2024, with the low at -$1.0 billion in Q3 2024.
• Historically, Enterprise Value has averaged -$797.8 million across 5 years, with a median of -$783.1 million in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 60.46% — and 2025, when it tumbled 64.76%.
• Agios Pharmaceuticals' Enterprise Value stood at -$783.1 million in 2022, then climbed by 0.79% to -$776.9 million in 2023, then retreated by 15.03% to -$893.7 million in 2024, then gained by 4.4% to -$854.4 million in 2025, then climbed by 13.74% to -$737.0 million in 2026.
• The last three Enterprise Value figures came in at -$737.0 million (Q1 2026), -$854.4 million (Q4 2025), and -$952.9 million (Q3 2025), per Business Quant data.